# Tarsus Pharmaceuticals

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/tarsus-pharmaceuticals
Canonical HTML page: https://getfinancebrief.com/entity/tarsus-pharmaceuticals

## Recent coverage (1 stories)

### Biotech Earnings: Tarsus and ORIC Signal Growth Amid Clinical Milestones
2026-02-23 22:50:08 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Tarsus Pharmaceuticals and ORIC Pharmaceuticals reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial scaling and clinical data maturation. While Tarsus focuses on the rapid adoption of XDEMVY, ORIC is advancing its oncology pipeline with key data readouts expected in 2026.
Full story: https://getfinancebrief.com/story/tarsus-oric-biotech-earnings-q4-2025

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.